Angiomodulators in cancer therapy

New perspectives

Lenka Varinska, Peter Kubatka, Jan Mojzis, Anthony Zulli, Katarina Gazdikova, Pavol Zubor, Dietrich Busselberg, Martin Caprnda, Radka Opatrilova, Iveta Gasparova, Martin Klabusay, Martin Pec, Eitan Fibach, Mariusz Adamek, Peter Kruzliak

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis.

Original languageEnglish
Pages (from-to)578-590
Number of pages13
JournalBiomedicine and Pharmacotherapy
Volume89
DOIs
Publication statusPublished - 1 May 2017

Fingerprint

MicroRNAs
Galectins
Biological Products
Neoplasms
Angiogenesis Inhibitors
Invertebrates
Therapeutics
Cell Movement
Blood Vessels
Carcinogenesis
Endothelial Cells
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Anti-angiogenics
  • Cancer therapy
  • Galectins
  • Marine natural products
  • microRNAs

ASJC Scopus subject areas

  • Pharmacology

Cite this

Varinska, L., Kubatka, P., Mojzis, J., Zulli, A., Gazdikova, K., Zubor, P., ... Kruzliak, P. (2017). Angiomodulators in cancer therapy: New perspectives. Biomedicine and Pharmacotherapy, 89, 578-590. https://doi.org/10.1016/j.biopha.2017.02.071

Angiomodulators in cancer therapy : New perspectives. / Varinska, Lenka; Kubatka, Peter; Mojzis, Jan; Zulli, Anthony; Gazdikova, Katarina; Zubor, Pavol; Busselberg, Dietrich; Caprnda, Martin; Opatrilova, Radka; Gasparova, Iveta; Klabusay, Martin; Pec, Martin; Fibach, Eitan; Adamek, Mariusz; Kruzliak, Peter.

In: Biomedicine and Pharmacotherapy, Vol. 89, 01.05.2017, p. 578-590.

Research output: Contribution to journalReview article

Varinska, L, Kubatka, P, Mojzis, J, Zulli, A, Gazdikova, K, Zubor, P, Busselberg, D, Caprnda, M, Opatrilova, R, Gasparova, I, Klabusay, M, Pec, M, Fibach, E, Adamek, M & Kruzliak, P 2017, 'Angiomodulators in cancer therapy: New perspectives', Biomedicine and Pharmacotherapy, vol. 89, pp. 578-590. https://doi.org/10.1016/j.biopha.2017.02.071
Varinska L, Kubatka P, Mojzis J, Zulli A, Gazdikova K, Zubor P et al. Angiomodulators in cancer therapy: New perspectives. Biomedicine and Pharmacotherapy. 2017 May 1;89:578-590. https://doi.org/10.1016/j.biopha.2017.02.071
Varinska, Lenka ; Kubatka, Peter ; Mojzis, Jan ; Zulli, Anthony ; Gazdikova, Katarina ; Zubor, Pavol ; Busselberg, Dietrich ; Caprnda, Martin ; Opatrilova, Radka ; Gasparova, Iveta ; Klabusay, Martin ; Pec, Martin ; Fibach, Eitan ; Adamek, Mariusz ; Kruzliak, Peter. / Angiomodulators in cancer therapy : New perspectives. In: Biomedicine and Pharmacotherapy. 2017 ; Vol. 89. pp. 578-590.
@article{389440e330e9450380dc350ecf57ffcd,
title = "Angiomodulators in cancer therapy: New perspectives",
abstract = "The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis.",
keywords = "Angiogenesis, Anti-angiogenics, Cancer therapy, Galectins, Marine natural products, microRNAs",
author = "Lenka Varinska and Peter Kubatka and Jan Mojzis and Anthony Zulli and Katarina Gazdikova and Pavol Zubor and Dietrich Busselberg and Martin Caprnda and Radka Opatrilova and Iveta Gasparova and Martin Klabusay and Martin Pec and Eitan Fibach and Mariusz Adamek and Peter Kruzliak",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.biopha.2017.02.071",
language = "English",
volume = "89",
pages = "578--590",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Angiomodulators in cancer therapy

T2 - New perspectives

AU - Varinska, Lenka

AU - Kubatka, Peter

AU - Mojzis, Jan

AU - Zulli, Anthony

AU - Gazdikova, Katarina

AU - Zubor, Pavol

AU - Busselberg, Dietrich

AU - Caprnda, Martin

AU - Opatrilova, Radka

AU - Gasparova, Iveta

AU - Klabusay, Martin

AU - Pec, Martin

AU - Fibach, Eitan

AU - Adamek, Mariusz

AU - Kruzliak, Peter

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis.

AB - The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis.

KW - Angiogenesis

KW - Anti-angiogenics

KW - Cancer therapy

KW - Galectins

KW - Marine natural products

KW - microRNAs

UR - http://www.scopus.com/inward/record.url?scp=85014061014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014061014&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2017.02.071

DO - 10.1016/j.biopha.2017.02.071

M3 - Review article

VL - 89

SP - 578

EP - 590

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -